PPCB - Propanc Biopharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3900
-0.0050 (-1.27%)
At close: 3:34PM EST
Stock chart is not supported by your current browser
Previous Close0.3950
Open0.3650
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3155 - 0.4000
52 Week Range0.0600 - 28.5000
Volume2,417
Avg. Volume12,103
Market Cap427,428
Beta (3Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-10.9700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.52
  • Business Wire

    Propanc Biopharma Provides Shareholder Update and Forecast for 2020

    Propanc Biopharma, Inc. (PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today an update on the progress of the Company, its R&D activities and forecast for 2020, as the Company plans to prepare for initiating a First-In-Human (FIH) study for its lead product, PRP, a novel formulation consisting of two proenzymes for the treatment and prevention of metastatic cancer from solid tumors in advanced cancer patients, which management hopes to commence in the second half of next year. According to a new market intelligence report by BIS Research, titled "Global Metastatic Cancer Treatment Market – Analysis and Forecast, 2018-2025", the global metastatic cancer treatment market was estimated at $54.11 billion in 2017, and is anticipated to reach $98.24 billion by 2025.

  • Propanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer Patients
    Business Wire

    Propanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer Patients

    Propanc Biopharma, Inc. (PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the mode of action of the company’s lead product candidate, PRP, a formulation consisting of two proenzymes, has been elucidated by the company’s researchers, by suppressing pathways relating to the Epithelial to Mesenchymal Transition (EMT) and metastasis. The EMT is a biological process by which cells become motile and invasive, but in cancer stem cells (CSCs), results in metastasis, a process whereby secondary tumors are formed often in remote distances from a primary tumor, causing the cancer to return and spread.

  • Business Wire

    Propanc Biopharma Appoints Carlo Campiciano as Chief Financial Officer

    Propanc Biopharma, Inc. (PPCB) (“Propanc”, the “Company”, “we”, “our”, or “us”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that Propanc has appointed Mr. Carlo Campiciano as its Chief Financial Officer, commencing July 1, 2019. Mr. Campiciano brings significant experience to the Company across a broad range of financial disciplines in the healthcare sector, including taxation, finance, operations, planning and financial strategy.

  • Business Wire

    Propanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory Board

    Propanc Biopharma, Inc. (PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has appointed Dr. Ralf Brandt to its Scientific Advisory Board (SAB). Dr. Brandt previously served as an Advisory Board member to Propanc over a seven-year period between 2011 and 2018.

  • PR Newswire

    Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

    MELBOURNE, Australia, March 25, 2019 /PRNewswire/ -- Propanc Biopharma, Inc. (PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has initiated development of a bio-analytical assay intended to quantify the active ingredients of the company's lead product candidate, PRP, in preparation for human trials, planned for later this year. PRP is a solution of two proenzymes, trypsinogen and chymotrypsinogen, administered by I.V. injection. "We are keen to undertake this important work, as the quantification of PRP in human serum will provide invaluable information that links the biodistribution of the two proenzymes, as it exerts its potent anti-cancer and anti-tumor effects, to the efficacy and safety of our therapy on patients at different dosing levels," said Dr. Julian Kenyon, Propanc's Chief Scientific Officer.

  • OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference
    PR Newswire

    OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

    OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...

  • PR Newswire

    Propanc Biopharma Receives Notice of Allowance for Additional Claims from Foundation Patent in the U.S.

    MELBOURNE, Australia, March 13, 2019 /PRNewswire/ -- Propanc Biopharma, Inc. (PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) confirming composition of matter claims involving trypsinogen and chymotryosinogen have been allowed. The additional composition claims are a continuation from the original foundation patent in the U.S. and as a result, both method of treatment and composition claims will protect the Company's lead product candidate, PRP, a pharmaceutical composition for treating cancer. A Notice of Allowance is issued by the USPTO to indicate that it believes an invention qualifies for a patent.

  • Business Wire

    Propanc Biopharma to Present at the 31st Annual ROTH Conference March 17 – 19, 2019

    Propanc Biopharma, Inc. (PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that its Chief Executive Officer, James Nathanielsz, has been invited to present at the 31st Annual ROTH Conference being held on March 17 – 19, 2019 at the Ritz Carlton, Laguna Niguel located in Orange County, California. Last year, the ROTH Conference hosted close to 550 participating companies and more than 4,700 attendees, including institutional investors, analysts, family offices and high net worth investors. ROTH will host a pre-recorded webcast of Propanc's presentation, which will be available on the conference website at http://wsw.com/webcast/roth33/ppcb/ beginning on March 11.

  • Business Wire

    Propanc Biopharma to Present at the 2019 BIO CEO & Investor Conference

    Propanc Biopharma, Inc. (PPCB) (“Propanc”), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that its Chief Executive Officer, James Nathanielsz, will be presenting at the 2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 9:45 am EST. “The BIO CEO & Investor Conference is one of the largest investor conferences, focused on established and emerging publicly traded and select private biotech companies, and I am honored to be selected to present at this year’s conference. As we prepare to transition our lead technology into human trials, this is a great opportunity for us to meet with investors and potential partners to provide a company update for 2019, focusing on the advancement of our lead product, PRP,” said James Nathanielsz, CEO and Executive Chairman of Propanc.

  • Business Wire

    Propanc Biopharma Commences Drug Discovery Research Collaboration

    Propanc Biopharma, Inc. (PPCB) ("Propanc"), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that a cooperation agreement has been entered into between the University of Jaén and Propanc to commence the POP1 joint drug discovery program to be co-funded by both parties. The agreement coincides with the appointment of research scientist, Mr. Aitor González, to lead the drug discovery and research activities over the next 3 to 4 years.